This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Impax Laboratories Reports Third Quarter 2012 Results

Stocks in this article: IPXL

The following table reconciles reported net income to adjusted net income.

      Three months ended       Nine months ended

(Unaudited, amounts in millions, except per share data)

September 30, September 30,
2012     2011 2012     2011
Net income $ 20.0 $ 17.2 $ 51.1 $ 43.6
Adjusted to add (deduct):
Amortization and acquisition-related costs (a) 22.1 - 36.4 -
Generic product withdrawal costs (b) 2.0 - 2.0 -
Patent litigation settlement reimbursement (c) (5.0 ) - (5.0 ) -
Gross profit earned on Zomig® Agreement - - 46.2 -
Acquisition related in process R&D - - 1.6 -
Employee severance - - 1.9 0.8
Inventory adjustment - - 3.5 -
Lower of cost or market charge - - 1.7 -
Income tax effect   (6.6 )   -   (30.4 )   (0.3 )
Adjusted net income $ 32.5   $ 17.2 $ 109.0   $ 44.1  
 
Net income adjusted per diluted share $ 0.48 $ 0.26 $ 1.60 $ 0.66
Net income per diluted share $ 0.29 $ 0.26 $ 0.75 $ 0.65
 
 

Impax Laboratories, Inc.

Non-GAAP Financial Measures
 

The following table reconciles reported net income to adjusted EBITDA.

      Three months ended       Nine months ended

(Unaudited, amounts in millions)

September 30, September 30,
2012     2011 2012     2011
Net income $ 20.0 $ 17.2 $ 51.1 $ 43.6
Adjusted to add (deduct):
Interest income (0.3 ) (0.3 ) (0.8 ) (0.9 )
Interest expense 0.1 0.1 0.6 0.1
Depreciation and other 4.3 3.5 11.9 11.9
Income taxes   9.6     8.5     27.2     20.8  
EBITDA   33.7     29.0     90.0     75.5  
 
Adjusted to add:
Amortization and acquisition-related costs (a) 22.1 - 36.4 -
Generic product withdrawal costs (b) 2.0 - 2.0 -
Patent litigation settlement reimbursement (c) (5.0 ) - (5.0 ) -
Gross profit earned on Zomig® Agreement - - 46.2 -
Acquisition related in process R&D - - 1.6 -
Employee severance - - 1.9 0.8
Inventory adjustment - - 3.5 -
Lower of cost or market charge - - 1.7 -
Share-based compensation   3.8     3.5     12.1     9.6  
Adjusted EBITDA $ 56.6   $ 32.5   $ 190.4   $ 85.9  
 
(a)     Amortization and acquisition-related costs from the January 2012 Distribution, License, Development and Supply Agreement with AstraZeneca UK Limited and the June 2012 Development, Distribution and Supply Agreement with TOLMAR, Inc.
 
(b) The Company recorded a charge of $2.0 million related to the voluntary withdrawal from the market of bupropion XL 300 mg, manufactured by Impax and marketed through our Strategic Alliance Agreement with Teva.
 
(c) The Company received $5.0 million for reimbursement of legal fees pursuant to the settlement of litigation.
 




6 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs